Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q4 2021 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company's clinical development programs and regulatory and commercial outlook. “We have been looking forward to 2022 for a long time, which we anticipate will be the most significant year for clinical data read-outs in the Company's history,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Despite the ongoing impac

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

Bausch Health Companies Inc

BioMarin Pharmaceutical

Global Blood Therapeutics

Theravance Biopharma

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

Aurinia Pharmaceuticals

Myovant Sciences

Cassava Sciences Inc

SPDR S&P Biotech ETF

Biotechs have been one of the worst performers for 2021 as the pandemic has wrought havoc in the sector. 2022 will likely entail a rotation out of high valuation sectors like technology into more depressed sectors like healthcare.

6 Top Biotech Ideas For 2022

Adaptimmune Therapeutics

The biotech bear market has punished these two stocks too severely at this point.

2 Cancer Stocks With Absurdly Low Valuations

The stock is significantly undervalued and this year could unlock significant near-term value in the form of ATHENA trial data.

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures. Unaudited preliminary results include: $35.5M - $36.1M in estimated Rubraca global product revenues for the fourth quarter of 2021 compared to $37.9M

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

Clovis Oncology has had a rough 2021, with Rubraca sales continuing to disappoint. The company's Q3 sales revealed a slight increase quarter-over-quarter and a slight decrease year-over-year. The company points to COVID-19 headwinds and a decrease in the number of new ovarian cancer diagnoses. I am leaning more towards the lackluster demand for PARP inhibitors.

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Why Is Clovis (CLVS) Down 32% Since Last Earnings Report?

Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.

Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2021 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company's clinical development programs and regulatory and commercial outlook. “While COVID-19 continues to impact our revenues, as fewer patients have been diagnosed and treated for ovarian cancer during the pandemic, it has not affected our development programs. We remain on track for an eventful 2022, with three data readouts

Clovis Oncology Announces Third Quarter 2021 Operating Results

Vinco Ventures

Bitfarms Ltd

Kala Pharmaceuticals

Meta Materials

Romeo Power

Senseonics Holdings

Electrameccanica

Voyager Therapeutics

Wish

If you're like most traders right now, you're looking for an edge.… The post Best Penny Stocks To Buy For A Short Squeeze?

Best Penny Stocks To Buy For A Short Squeeze? 10 To Watch Today

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

BOULDER, Colo. & MUNICH--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITM's therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu), EndolucinBeta®, for use in the clinical development of FAP-2286, Clovis' fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the firs

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

MUNICH & BOULDER, Colo.--(BUSINESS WIRE)--ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITM's therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu), EndolucinBeta®, for use in the clinical development of FAP-2286, Clovis' fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the firs

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

LaZBoy

Pulmatrix

Sunopta

Tapestry

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Bet on Rising P/E Investing With These Top 5 Stocks

ACADIA Pharma

Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.

Can These Former Biotech Growth Stocks Regain Their Form?

Harmony Gold Mining Co Ltd

Why top investors are watching these penny stocks right now The post 3 Penny Stocks That Top Investors Are Watching in October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Clovis Oncology Stock (CLVS)